.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,078,816

« Back to Dashboard

Details for Patent: 9,078,816

Title:Buccal, polar and non-polar spray containing ondansetron
Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: aqueous polar solvent, ondansetron, optionally flavoring agent, and propellant; formulation III: non-polar solvent, ondansetron, and optional flavoring agent; formulation IV: non-polar solvent, ondansetron, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, ondansetron, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, ondansetron, optional flavoring agent, and propellant.
Inventor(s): Dugger, III; Harry A. (Flemington, NJ), Abd El-Shafy; Mohammed (Hauppauge, NY)
Assignee: Suda Ltd. (Osborne Park, AU)
Filing Date:Apr 12, 2012
Application Number:13/445,331
Claims:1. A propellant free oral spray composition for transmucosal administration of ondansetron or a pharmaceutically acceptable salt thereof comprising: ondansetron or a pharmaceutically acceptable salt thereof in an amount of between 0.01 and 40 percent by weight of the total composition; and a mixture of a polar solvent and a non-polar solvent in an amount between 60.9 and 97.06 percent by weight of the total composition, wherein the non-polar solvent is selected from the group consisting of (C.sub.2-C.sub.24) fatty acid (C.sub.2-C.sub.6) esters, C.sub.7-C.sub.18 hydrocarbons of linear or branched configuration, C.sub.2-C.sub.6 alkanoyl esters, and triglycerides of C.sub.2-C.sub.6 carboxylic acids.

2. The composition of claim 1, wherein the polar solvent is selected from the group consisting of: polyethyleneglycols having a molecular weight between 400 and 1000, C.sub.2 to C.sub.8 mono- and poly-alcohols, and C.sub.7 to C.sub.18 alcohols of linear or branched configuration.

3. The composition of claim 1, wherein the polar solvent and non-polar solvents are present in a ratio of polar solvent to non-polar solvent of 1:99 to 99:1, 60:40 to 40:60, or 50:50.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc